Literature DB >> 12586023

[Oxazolidinones and glycopeptides].

Carlos Pigrau1.   

Abstract

We review the chemical structure, pharmacokinetics, antimicrobial spectrum, mechanisms of action and resistance, clinical use and adverse effects of oxazolidinones (linezolid) and glycopeptides. Oxazolidinones inhibit protein synthesis and glycopeptides cell wall synthesis. Antibacterial spectra cover grampositive pathogens, including multiresistant organisms. Linezolid has a 100% absorption and can be administered orally or intravenously; it is cleared by renal and hepatic routes, thus dose adjustments are not needed in moderate renal or hepatic failure. Oral absorption of glycopeptides is minimal. They are excreted by the kidneys (dose adjustments are needed in renal failure). The main clinical indications are the treatment of infections caused by grampositive pathogens; linezolid is also useful for infections caused by glycopeptide-resistant enterococcal infections. Linezolid can cause trombocytopenia when treatment lasted longer than two weeks. The main side effect of vancomycin is its nefrotoxicity and teicoplanin can cause fever.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586023     DOI: 10.1016/s0213-005x(03)72907-3

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  2 in total

1.  In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis.

Authors:  Alejandra Gomez-Flores; Oliverio Welsh; Salvador Said-Fernández; Gerardo Lozano-Garza; Roman Erick Tavarez-Alejandro; Lucio Vera-Cabrera
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Antibacterial activity of new oxazolidin-2-one analogues in methicillin-resistant Staphylococcus aureus strains.

Authors:  Jesús Córdova-Guerrero; Esteban Hernández-Guevara; Sandy Ramírez-Zatarain; Marco Núñez-Bautista; Adrián Ochoa-Terán; Raquel Muñiz-Salazar; Julio Montes-Ávila; Gabriela López-Angulo; Armando Paniagua-Michel; Gustavo A Nuño Torres
Journal:  Int J Mol Sci       Date:  2014-03-26       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.